TrumpRx lists many medicines at prices higher than paid in UK | Reuters Skip to main content Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv U.S. dollar banknotes and medicines are seen in this illustration taken, June 27, 2024. REUTERS/Dado Ruvic/Illustration/File Photo Purchase Licensing Rights, opens new tab March 18 (Reuters) - U.S. President Donald Trumppledged to make prescription drugs cheaper for Americans than anywhere in the world, but his TrumpRx.gov ...

In a 3-0 decision, the 9th U.S. Circuit Court of Appeals in Pasadena, California said AbbVie (ABBV.N), opens new tab, AstraZeneca (AZN.L), opens new tab, Novartis (NOVN.S), opens new taband Sanofi (SASY.PA), opens new tabmust defend against claims they violated the federal False Claims Act through their involvement in the Section 340B Drug Pricing Program. Big drugmakers must face US overcharge claims on medications for low-income patients | Reuters Skip to main content Exclusive news, data and analytics fo ...

Key Takeaways AbbVie fell below its 50-day SMA, hinting at short-term weakness, but remains above 200-day trendSkyrizi and Rinvoq drove growth with $26B sales in 2025, expected to exceed $31B in 2026Humira erosion and weak aesthetics sales persist, but pipeline, M&A, and new drugs support growthAbbVie (ABBV) stock slipped below its 50-day simple moving average (SMA) on March 13, after consistently trading above it since mid-Feb. However, the stock has remained comfortably above its 200-day SMA for more than ...

Core Insights - Generative AI is viewed as a transformative technology by Amazon's CEO Andy Jassy, indicating its potential to significantly enhance customer experiences across the company [1] - Elon Musk predicts that by 2040, humanoid robots could create a market worth $250 trillion, representing a major shift in the global economy driven by AI innovation [2][3] - Major firms like PwC and McKinsey acknowledge the potential of AI to unlock multi-trillion-dollar opportunities, reinforcing the optimistic outlook on AI's economic impact [3] Company and Industry Analysis - A breakthrough in AI technology is seen as a catalyst for redefining work, learning, and creativity, leading to increased interest from hedge funds and top investors [4] - There is speculation about an under-owned company that may play a crucial role in the AI revolution, suggesting that it could be a significant investment opportunity [4][6] - Prominent figures in technology and finance, including Bill Gates and Warren Buffett, recognize AI as a major technological advancement with the potential for substantial social benefits [8]

Core Thesis - AbbVie Inc. is viewed positively due to its successful transition from Humira, with a diversified drug portfolio and strong growth potential in the biopharmaceutical sector [1][6]. Financial Performance - AbbVie’s share price was $227.68 as of March 11th, with trailing and forward P/E ratios of 96.07 and 15.65 respectively [1]. - The company has seen its shares rebound, rising over 20% in 2025, indicating market confidence in its growth strategy [5]. Product Portfolio - AbbVie is navigating the post-Humira era by launching new therapies in immunology and oncology, with Skyrizi and Rinvoq generating combined sales of $6.9 billion [3][4]. - The company projects sales of $31 billion in 2027 and $40 billion by 2029 for its immunology drugs, indicating strong future revenue potential [4]. Pipeline and Development - AbbVie has an extensive pipeline with 20 drugs in phase III trials and over 50 in earlier development stages, targeting high-demand areas such as blood cancers and Parkinson's disease [4]. Dividend and Income Stability - AbbVie offers a $6.92 annual dividend, yielding 3.1%, and has a 53-year history of annual dividend increases, averaging 12.5% growth over the past decade [5].

Core Viewpoint - Large-cap biotech stocks are considered resilient to disruption risks typically faced by tech companies, primarily due to their long drug approval processes and established product portfolios [1][2] Group 1: Biotech Sector Resilience - Companies like Amgen and AbbVie are highlighted for their ability to navigate revenue erosion through broad product portfolios and multi-year pipeline replacements [1] - The FDA approval process, which can take a decade, provides a structural time buffer that protects biotech firms from rapid obsolescence [1] - Year-to-date performance shows Amgen up 16% and Gilead up 21% in 2026, significantly outperforming the iShares Biotechnology ETF, which is up approximately 3% [1] Group 2: Disruption Mechanisms - While biotech firms are insulated from AI-driven disruption, they face challenges such as patent cliffs, biosimilar competition, and government drug pricing reforms [1] - AbbVie’s Humira lost exclusivity, leading to a revenue drop of about 50% in two years, highlighting the risks associated with patent cliffs [1] - Amgen's revenue from Enbrel fell 48% in Q4 2025 due to biosimilar competition and Medicare redesign, indicating structural revenue erosion [1] Group 3: Company-Specific Insights - Gilead's ASCENT-07 trial for Trodelvy missed its primary endpoint, demonstrating how clinical trial failures can significantly impact pipeline value [2] - Eli Lilly's stock has appreciated approximately 416% over five years, driven by the success of its GLP-1 products, but it is down 6% year-to-date in 2026 [2] - Biogen's revenue is expected to decline mid-single digits in 2026, with its MS franchise down 14% in Q4 2025, reflecting a different risk profile compared to other biotech firms [2] Group 4: Evaluating Biotech Stocks - Investors should assess biotech stocks based on three questions: the percentage of revenue from products with patent protection beyond five years, the presence of at least two Phase 3 pipeline products, and the strength of the balance sheet to support pipeline investments [2] - Amgen's CEO expressed confidence in the company's broad portfolio and innovative therapies, indicating a path for sustained long-term growth [2] - Understanding the specific types of disruption, such as patent cliffs and pricing reform, is crucial for investors to navigate volatility in the biotech sector [2]

Equity markets have been volatile this year, and market downturns have a way of testing even the most confident investors. Amid geopolitical tensions and lingering tariff-related uncertainty, some fear the stock market could take a turn for the worse by the end of the year, though no one can know for sure. But history shows that some of the best long-term investment opportunities emerge precisely when uncertainty is at its highest. Will AI create the world's first trillionaire? Our team just released a r ...

Core Viewpoint - Harbor Capital is an asset manager that focuses on a carefully selected range of active ETFs aimed at generating attractive, risk-adjusted returns within investment portfolios [1] Group 1 - The company emphasizes the importance of curating a select suite of active ETFs [1] - Harbor Capital believes that their chosen ETFs have the potential to deliver compelling returns [1] - The management of the account is not conducted by Harbor Capital, and communications through Seeking Alpha will not be addressed [1]

Core Insights - The article discusses the promising clinical data for AbbVie’s Amylin analog ABBV-295, which shows significant weight loss potential compared to placebo groups [5][8] - ABBV-295 demonstrates early efficacy that surpasses competitors like Roche's petrelintide and Novo Nordisk's Cagrilintide, although it requires improvements in safety, particularly regarding gastrointestinal side effects [5][7] Summary by Sections Clinical Data - After 12 weeks of weekly dosing, participants experienced a weight loss of -7.75% to -9.79%, while the placebo group showed a minimal change of -0.26% [5][6] - In the 13th week, with adjusted dosing schedules, weight loss remained significant at -7.86% to -9.73% [5][6] Molecular Design and Treatment Potential - ABBV-295's molecular design combines fragments of human adrenomedullin and amylin, optimized for stability and extended half-life, indicating potential as a long-acting weight loss medication [7] - Future combination therapies may enhance efficacy, as Cagrilintide has shown advantages in combination treatments, and Roche is exploring the use of petrelintide with GLP-1/GIP dual receptor agonists [7] Market Dynamics - AbbVie invested $350 million upfront and $1.875 billion in milestone payments for ABBV-295, highlighting its commitment to the long-acting weight loss drug market [8] - The competitive landscape includes major players like Pfizer and Novo Nordisk, with Pfizer acquiring Metsera and Novo Nordisk launching an oral amylin/GLP-1 dual-target drug that achieved a 13.1% weight reduction in 12 weeks [8] - The future of the weight loss drug market will likely focus on safety, efficacy, and the potential for combination therapies to capture market share [8]

Growth Prospects - The company is optimistic about its growth prospects, projecting a revenue of $67 billion for 2026 and maintaining high single-digit growth through the decade [2] - There is confidence in the portfolio of assets that are currently in place, which are considered market derisked, supporting robust growth into the next decade [2] Margin Profile - The company has a clear strategy to drive growth, with a focus on key products like SKYRIZI, which is expected to contribute significantly to the overall growth trajectory [2]